A Pilot Study of Paricalcitol Synergism in Conjunction With Standard-of-Care Chemo-Radiation for Resectable Rectal Cancers.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2018
At a glance
- Drugs Paricalcitol (Primary) ; Fluorouracil
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 10 Jun 2017 Biomarkers information updated
- 31 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Apr 2012 Planned end date changed from 1 Dec 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.